Syndopa CR 50 200 mg

Syndopa CR 50 200 mg is a sustained-release combination of Carbidopa and Levodopa for treating Parkinson’s disease and syndrome. Parkinson’s is a chronic disease defined as slow and unsteady movement, tremors, and muscular stiffness. If left untreated, this syndrome can cause difficulty performing normal daily activities. It is supplied as a tablet for oral administration. The tablets are formulated to slowly release two active ingredients: Carbidopa and Levodopa. It is believed that Parkinson’s is caused due to lack of dopamine, a chemical produced naturally by certain brain cells. This chemical plays a crucial role in receiving messages in certain regions of the brain that control muscle movement. Problem with body movements develops when too little dopamine is produced. Levodopa replaces dopamine in the brain, while carbidopa ensures that an adequate amount of Levodopa gets into the brain where it is required. In many patients, this causes a significant reduction in Parkinson’s disease symptoms.